Abstract
Tumor cells often have defects in DNA repair pathways that make them vulnerable to specific DNA-damaging anticancer agents. The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer drugs are active areas of scientific investigation that may help rationalize and improve cancer chemotherapy. This article reviews the available data on the influence of defects in proteins involved in the major DNA repair pathways (i.e., homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, mismatch repair, Fanconi anemia repair, translesion synthesis and direct reversal repair) on the cytotoxicity of the FDAapproved anticancer drugs. It is shown that specific deficiencies in these DNA repair pathways alter the cytotoxicity of 60 anticancer drugs, including classical DNA-targeting drugs (e.g., alkylating agents, cytotoxic antibiotics, DNA topoisomerase inhibitors and antimetabolites) and other drugs whose primary pharmacological target is not the DNA (e.g., antimitotic agents, hormonal and targeted therapies). This information may help predict response to anticancer drugs in patients with tumors having specific DNA repair defects.
Keywords: Anticancer, chemotherapy, DNA damage, DNA damage response.
Current Medicinal Chemistry
Title:Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Volume: 21 Issue: 30
Author(s): Jose Manuel Calderon-Montano, Estefania Burgos-Moron, Manuel Luis Orta and Miguel Lopez-Lazaro
Affiliation:
Keywords: Anticancer, chemotherapy, DNA damage, DNA damage response.
Abstract: Tumor cells often have defects in DNA repair pathways that make them vulnerable to specific DNA-damaging anticancer agents. The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer drugs are active areas of scientific investigation that may help rationalize and improve cancer chemotherapy. This article reviews the available data on the influence of defects in proteins involved in the major DNA repair pathways (i.e., homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, mismatch repair, Fanconi anemia repair, translesion synthesis and direct reversal repair) on the cytotoxicity of the FDAapproved anticancer drugs. It is shown that specific deficiencies in these DNA repair pathways alter the cytotoxicity of 60 anticancer drugs, including classical DNA-targeting drugs (e.g., alkylating agents, cytotoxic antibiotics, DNA topoisomerase inhibitors and antimetabolites) and other drugs whose primary pharmacological target is not the DNA (e.g., antimitotic agents, hormonal and targeted therapies). This information may help predict response to anticancer drugs in patients with tumors having specific DNA repair defects.
Export Options
About this article
Cite this article as:
Calderon-Montano Manuel Jose, Burgos-Moron Estefania, Orta Luis Manuel and Lopez-Lazaro Miguel, Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review, Current Medicinal Chemistry 2014; 21 (30) . https://dx.doi.org/10.2174/0929867321666140601203816
DOI https://dx.doi.org/10.2174/0929867321666140601203816 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety of One-week, First-line, Standard Triple Therapy for Helicobacter pylori Eradication in a Japanese Population
Current Drug Safety Inhibition of Bacterial Carbonic Anhydrases and Zinc Proteases: From Orphan Targets to Innovative New Antibiotic Drugs
Current Medicinal Chemistry Compounds from Wild Mushrooms with Antitumor Potential
Anti-Cancer Agents in Medicinal Chemistry 4-Methylumbelliferones Analogues as Anticancer Agents: Synthesis and in Cell Pharmacological Studies
Anti-Cancer Agents in Medicinal Chemistry Control of Tumor Markers Using Nanotechnology
Mini-Reviews in Medicinal Chemistry A Review on the Monoacylglycerol Lipase: At the Interface Between Fat and Endocannabinoid Signalling
Current Medicinal Chemistry New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia
Current Pharmaceutical Design Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy
Current Radiopharmaceuticals Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia
Current Pharmacogenomics Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Genomic Instability and Carcinogenesis: An Update
Current Genomics Are Carbonic Anhydrase Inhibitors Suitable for Obtaining Antiobesity Drugs ?
Current Pharmaceutical Design The Use of Gene Therapy Tools in Reproductive Immunology Research
Current Gene Therapy Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Carbohydrate based Potential Chemotherapeutic Agents: Recent Developments and their Scope in Future Drug Discovery
Mini-Reviews in Medicinal Chemistry Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives
Current Pharmaceutical Design Obesity: Current Treatment and Future Horizons
Mini-Reviews in Medicinal Chemistry Molecular Biology of Nucleoside Transporters and their Distributions and Functions in the Brain
Current Topics in Medicinal Chemistry Probiotic Properties of a Spaceflight-induced Mutant Lactobacillus Plant- arum SS18-50 in Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets